Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

174.53USD
19 Apr 2018
Change (% chg)

$-0.58 (-0.33%)
Prev Close
$175.11
Open
$174.47
Day's High
$174.90
Day's Low
$174.11
Volume
33,519
Avg. Vol
1,621,129
52-wk High
$201.23
52-wk Low
$152.16

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 30.95 32.74
EPS (TTM): 11.00 -- --
ROI: 11.98 14.84 14.38
ROE: 26.43 16.34 16.07

Amgen's Aimovig halved migraine days in 30 percent of trial patients

LOS ANGELES A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.

18 Apr 2018

Amgen's Aimovig halved migraine days in 30 pct of trial patients

LOS ANGELES, April 17 A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.

18 Apr 2018

BRIEF-Amgen Says CEO Robert Bradway's FY 2017 Total Compensation Was $16.9 Mln

* AMGEN INC SAYS CEO ROBERT BRADWAY'S FY 2017 TOTAL COMPENSATION WAS $16.9 MLN VS $16.9 MLN IN FY 2016 - SEC FILING Source text: [https://bit.ly/2EDxA7i] Further company coverage:

12 Apr 2018

BRIEF-Amgen Plans To Build A New Biomanufacturing Plant in Rhode Island

* AMGEN ANNOUNCES RHODE ISLAND WILL BE LOCATION OF FIRST US NEXT-GENERATION BIOMANUFACTURING PLANT

10 Apr 2018

Rhode Island governor says Amgen will build another plant in state

April 10 Amgen Inc will build a $165 million next-generation biopharmaceutical plant adjacent to its existing West Greenwich, Rhode Island manufacturing campus, the state governor's office told Reuters on Tuesday.

10 Apr 2018

BRIEF-‍European Commission Approves Expanded Indication For Amgen's Xgeva

* ‍EUROPEAN COMMISSION APPROVES EXPANDED INDICATION FOR AMGEN'S XGEVA (DENOSUMAB) FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA​ Source text for Eikon: Further company coverage:

03 Apr 2018

FDA expands use of Amgen leukemia drug Blincyto to patients with relapse risk

The U.S. Food and Drug Administration on Thursday expanded the use of Amgen Inc's leukemia drug Blincyto to include patients who are in remission but still have residual signs of the disease.

30 Mar 2018

UPDATE 1-FDA expands use of Amgen leukemia drug Blincyto to patients with relapse risk

March 29 The U.S. Food and Drug Administration on Thursday expanded the use of Amgen Inc's leukemia drug Blincyto to include patients who are in remission but still have residual signs of the disease.

30 Mar 2018

FDA expands use of Amgen leukemia drug Blincyto to patients with relapse risk

March 29 The U.S. Food and Drug Administration on Thursday expanded the use of Amgen Inc's leukemia drug Blincyto to include patients who are in remission but still have residual signs of the disease.

29 Mar 2018

Esperion's drug clears study as add-on cholesterol treatment

Esperion Therapeutics Inc said on Tuesday its experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients, who were already on another treatment to lower the risk of artery-clogging heart disease.

27 Mar 2018

Earnings vs. Estimates